Get notified of page updates
Glossary on
off
Printer Friendly Page
Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After First-Line Treatment in Advanced Triple Negative Breast Cancer (KEYLYNK-009)
Clinicaltrials.gov identifier:
NCT04191135
Study Contact Information:
For additional information, please contact:
Toll Free Number: 1-888-577-8839 or email: [email protected]
Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After First-Line Treatment in Advanced Triple Negative Breast Cancer (KEYLYNK-009)
About the Study
This study will look at how people with advanced () respond to different combinations of drugs. The study will look at two different treatment periods:
- Initial period: during this initial study period, participants will receive a combination of chemotherapy and drugs. Participants with stable cancer or an improvement will be able to continue to the next part of the study.
- Followup period: Continuing participants will be assigned to one of two groups. One group will receive the same drug combination during the followup period. The second group will instead plus a type of known as a during the follow-up period.
NOTE: This study is no longer enrolling patients.
This Study is Open To:
NOTE: This study is no longer enrolling patients.
This Study is Not Open To: